Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Emerg Infect Dis ; 13(10): 1484-90, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18257991

RESUMO

The control of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) is compromised by low sensitivity of the routinely used parasitologic confirmation tests. More sensitive alternatives, such as mini-anion exchange centrifugation technique (mAECT) or capillary tube centrifugation (CTC), are more expensive. We used formal decision analysis to assess the cost-effectiveness of alternative HAT confirmation algorithms in terms of cost per life saved. The effectiveness of the standard method, a combination of lymph node puncture (LNP), fresh blood examination (FBE), and thick blood film (TBF), was 36.8%; the LNP-FBE-CTC-mAECT sequence reached almost 80%. The cost per person examined ranged from euro1.56 for LNP-FBE-TBF to euro2.99 for LNP-TBF-CTC-mAECT-CATT (card agglutination test for trypanosomiasis) titration. LNP-TBF-CTC-mAECT was the most cost-effective in terms of cost per life saved. HAT confirmation algorithms that incorporate concentration techniques are more effective and efficient than the algorithms that are currently and routinely used by several T.b. gambiense control programs.


Assuntos
Técnicas de Apoio para a Decisão , Parasitologia/métodos , Tripanossomíase Africana/diagnóstico , Algoritmos , Análise Custo-Benefício , Humanos , Tripanossomíase Africana/sangue
2.
Trop Med Int Health ; 10(4): 347-56, 2005 Apr.
Artigo em Francês | MEDLINE | ID: mdl-15807799

RESUMO

INTRODUCTION: Population screening for human African trypanosomiasis (HAT) is often based on a combination of two screening tests: lymph node palpation (LN) and card agglutination test for trypanosomiasis (CATT). This decision analysis compared the efficiency of three alternative detection strategies: screening by LN only, CATT only and their combination (LN and CATT). METHOD: An HAT detection strategy was defined as the sequence of screening and confirmation. Efficacy was evaluated in terms of lives saved. The cost of screening and confirmation tests was estimated in US$. The different parameters in the decision tree were based on published literature and observations of the HAT control programme in the Democratic Republic of Congo. A sensitivity analysis was carried out on those parameters subject to uncertainty. RESULTS: The cost-effectiveness of a detection strategy based on CATT was US $125 per life saved, compared with US $517 for LN and US $452 for the combined. Marginal cost to add LN to CATT only was between US $1225 and US $5000 per life saved. Sensitivity analysis shows that these results are robust to variation. DISCUSSION: The CATT strategy was the most efficient. None of the strategies was able to avoid more than 60% of HAT deaths. This moderate efficacy is due to the low sensitivity of the confirmatory (diagnostic) tests. Substantial efficiency gains can be obtained by adopting a CATT only strategy and resources can be better allocated to more sensitive confirmatory tests or to increasing the coverage of populations at risk.


Assuntos
Trypanosoma brucei gambiense , Tripanossomíase Africana/diagnóstico , Testes de Aglutinação/economia , Animais , Análise Custo-Benefício , Técnicas de Apoio para a Decisão , República Democrática do Congo , Custos de Cuidados de Saúde , Humanos , Linfonodos , Programas de Rastreamento/economia , Programas de Rastreamento/métodos , Palpação , Sensibilidade e Especificidade , Tripanossomíase Africana/economia
3.
Bull World Health Organ ; 82(5): 381-4, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15298229

RESUMO

The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. Combination therapy has been suggested as being an available and potentially lasting solution to this impending crisis. However, the current cost of combination therapy, and especially that of artemisinin combination therapy (ACT), is potentially a serious drawback, even if a significant part of its cost is passed on to the end-user. If the question of cost is not successfully addressed this could lead to adverse results from the deployment of combination therapy as first-line treatment. These adverse effects range from an increase in potentially fatal delays in infected individuals presenting to medical services, to exclusion of the poorest malaria sufferers from receiving treatment altogether. Urgent steps are needed to reduce the cost of combination therapy to the end-user in a sustainable way if it is to be usable, and some possible approaches are discussed.


Assuntos
Antimaláricos/farmacologia , Surtos de Doenças/prevenção & controle , Malária Falciparum/tratamento farmacológico , Malária Falciparum/epidemiologia , Plasmodium falciparum/efeitos dos fármacos , África/epidemiologia , Animais , Antimaláricos/economia , Antimaláricos/uso terapêutico , Artemisininas/economia , Artemisininas/farmacologia , Artemisininas/uso terapêutico , Custos de Medicamentos , Resistência a Múltiplos Medicamentos , Humanos , Malária Falciparum/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA